Hot Investor Mandate: Corporate Venture Arm of Global Company Focuses on Therapeutics Investments in Oncology, GI, Rare Diseases, and More

12 Aug

A corporate venture capital arm of a global company seeks to make strategic investments into early-stage companies that are aligned with the parent company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the parent company’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent company.

The firm core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: